Suven Pharma - Product Mix Takes Toll On Margins, Thesis Unchanged: Anand Rathi
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Anand Rathi Report
Driven by 51.3% growth in contract development and manufacturing organisation pharma and 36.8% in contract development and manufacturing organisation specialty chemicals, Suven Pharmaceuticals Ltd.’s Q4 revenue grew 40% to Rs 2.6 billion.
The Ebitda margin softened 529 basis points to 36.2% due to a change in the product mix and higher freight and overhead costs due to Covid-19.
In spite of a challenging H1 FY21, revenue grew 21.1% and the FY21 Ebitda margin came at 43.6%.
Management aims at 10-15% revenue growth in FY22.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.